Mp72-14 discordance Between Patient-Reported Incontinence and Patient-Reported Pad Use Following Permanent Prostate Brachytherapy

Abstract

therapy that is optimal for disease control in patients with HR-LPCa. In this study, we compared the long-term oncological outcomes of RP and intensity-modulated radiation therapy (IMRT) for HR-LPCa at our institution using a propensity score-matched analysis.METHODS: We retrospectively reviewed 62 patients with HR-LPCa who underwent RP and 107 patients who received IMRT between 1999 and 2011. After adjusting for age, prostate-specific antigen (PSA) level, biopsy Gleason score, and clinical tumor (T)stage using a propensity score-matched analysis, the rates of castration-resistant prostate cancer-free (CRPC-F), cancer-specific survival (CSS), and overall survival (OS) were compared between the RP and IMRT groups using Kaplan-Meier analysis.RESULTS: After propensity score matching, 52 patients were assigned to each of the study groups, and age, initial PSA level, biopsy Gleason score, and clinical T-stage were matched exactly. The median follow-up durations in the RP and IMRT groups were 105 and 97 months, respectively. ADT was administered as a combination therapy to 27% and 77% of patients in the RP and IMRT groups, respectively. The 10-year CSS and OS rates were not significantly different between the RP and IMRT groups (CSS rate, 92.6% and 97.9%, respectively; p [ 0.519 and OS rate, 88.6% and 91.6%, respectively; p [ 0.635). The 10-year CRPC-F rate was not different between the RP and IMRT groups (16.0% and 16.0%, respectively); however, the 13-year CRPC-F rate was significantly higher in the RP group than in the IMRT group (58.9% and 16.0%, respectively; p [ 0.038).CONCLUSIONS: Long-term survival outcomes are not different between RP and IMRT. However, in late stages, RP may be superior to IMRT with respect to CRPC-F survival.